ALT

Altimmune Inc

Altimmune (NASDAQ:ALT) Shares Down 6.6% - Here's What Happened...

Intech Investment Management LLC lifted its position in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 102.9% during the second quarter, according to the company in its most recent Form 13F...

Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the company, MarketBeat...

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) saw some unusual options trading on Monday. Investors bought 11,978 call options on the company. This is an increase of 103% compared to the typical...

The average of price targets set by Wall Street analysts indicates a potential upside of 250.6% in Altimmune (ALT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Retail traders focused on AI-driven biopsy findings and clearer dose-response exuded increased confidence in pemvidutide’s potential.

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Analysts at HC Wainwright boosted their FY2025 earnings per share estimates for shares of Altimmune in a research note issued to investors on Tuesday...

Altimmune (NASDAQ:ALT - Get Free Report) announced its earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29...

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT Altimmune, Inc. Securities Fraud Class Action Lawsuit...